Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Change From Time-Matched Baseline Over Time in Ambulatory Blood Pressure Monitoring (ABPM) 24-hour Averages of Systolic Blood Pressure

24-hour average is the average of ABPM assessments over 24 hour intervals from the time of dosing. Time-matched baseline is the 24 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Daytime (12-Hour) Averages of Systolic Blood Pressure

Daytime 12-hour average is the average of ABPM assessments over daytime 12-hour intervals from the time of dosing. Time-matched baseline is the daytime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Nighttime (12-Hour) Averages of Systolic Blood Pressure

Nighttime 12-hour average is the average of ABPM assessments over nighttime 12-hour intervals from the time of dosing. Time-matched baseline is the nighttime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM 4-hour Averages of Systolic Blood Pressure

Postdose is the average of assessments over 4-hour intervals from the time of dosing that day. Time-matched baseline is the corresponding 4-hour average on Day -1.

Time frame: Time-matched baseline (Day -1), Days 1, 7, 14: 0-4, 4-8, 8-12, 12-16, 16-20, 20-24 hours postdose

Change From Time-Matched Baseline Over Time in ABPM 24-hour Averages of Mean Arterial Pressure

24-hour average is the average of ABPM assessments over 24 hour intervals from the time of dosing. Time-matched baseline is the 24 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Daytime (12-hour) Averages of Mean Arterial Pressure

Daytime 12-hour average is the average of ABPM assessments over daytime 12-hour intervals from the time of dosing. Time-matched baseline is the daytime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Nighttime (12-Hour) Averages of Mean Arterial Pressure

Nighttime 12-hour average is the average of ABPM assessments over nighttime 12-hour intervals from the time of dosing. Time-matched baseline is the nighttime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM 4-hour Averages of Mean Arterial Pressure

Postdose is the average of assessments over 4-hour intervals from the time of dosing that day. Time-matched baseline is the corresponding 4-hour average on Day -1.

Time frame: Time-matched baseline (Day -1), Days 1, 7, 14: 0-4, 4-8, 8-12, 12-16, 16-20, 20-24 hours postdose

Change From Time-Matched Baseline Over Time in ABPM 24-hour Averages of Diastolic Blood Pressure

24-hour average is the average of ABPM assessments over 24 hour intervals from the time of dosing. Time-matched baseline is the 24 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Daytime (12-hour) Averages of Diastolic Blood Pressure

Daytime 12-hour average is the average of ABPM assessments over daytime 12-hour intervals from the time of dosing. Time-matched baseline is the daytime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Nighttime (12-Hour) Averages of Diastolic Blood Pressure

Nighttime 12-hour average is the average of ABPM assessments over nighttime 12-hour intervals from the time of dosing. Time-matched baseline is the nighttime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM 4-hour Averages of Diastolic Blood Pressure

Postdose is the average of assessments over 4-hour intervals from the time of dosing that day. Time-matched baseline is the corresponding 4-hour average on Day -1.

Time frame: Time-matched baseline (Day -1), Days 1, 7, 14: 0-4, 4-8, 8-12, 12-16, 16-20, 20-24 hours postdose

Change From Time-Matched Baseline Over Time in ABPM 24-hour Averages of Pulse

24-hour average is the average of ABPM assessments over 24 hour intervals from the time of dosing. Time-matched baseline is the 24 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Daytime (12-hour) Averages of Pulse

Daytime 12-hour average is the average of ABPM assessments over daytime 12-hour intervals from the time of dosing. Time-matched baseline is the daytime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM Nighttime (12-Hour) Averages of Pulse

Nighttime 12-hour average is the average of ABPM assessments over nighttime 12-hour intervals from the time of dosing. Time-matched baseline is the nighttime 12 hours average during Day -1.

Time frame: Time Matched Baseline (Day -1), Days 1, 7, and 14

Change From Time-Matched Baseline Over Time in ABPM 4-hour Averages of Pulse

Postdose is the average of assessments over 4-hour intervals from the time of dosing that day. Time-matched baseline is the corresponding 4-hour average on Day -1.

Time frame: Time-matched baseline (Day -1), Days 1, 7, 14: 0-4, 4-8, 8-12, 12-16, 16-20, 20-24 hours postdose

Change From Baseline in Reactive Hyperemia Index (RHI) on Day 13

RHI is a measure of the extent of vessel dilatation and augmentation in vascular blood flow after a prespecified period of flow interruption. RHI is determined as the ratio of the post-to-pre- occlusion peripheral arterial tonometry amplitude of the tested (occluded) arm, divided by the post to-pre-occlusion ratio of the control arm. RHI values \>1.67 indicate normal endothelial function, while values ≤1.67 indicate endothelial dysfunction.

Time frame: Baseline, Day 13 predose AM

Post-Baseline Platelet Reactivity on Days 8 and 14: P2Y12 Reaction Units (PRU) Assay

Platelet reactivity, as measured by VerifyNow PRU assay, and presented as number of participants with \< 180 PRU or ≥ 180 PRU post-baseline (Days 8 and 14), by baseline category. The VerifyNow PRU assay measures effects on platelet activation caused by inhibition of the platelet receptor, P2Y12. This receptor is activated by adenosine 5'-diphosphate (ADP) in the cascade leading to platelet aggregation but can be blocked by P2Y12 inhibitor drugs, such as clopidogrel. Blockage of this receptor diminishes platelet activation and the ability of platelets to bind to fibrinogen. VerifyNow PRU assay values \< 180 units indicate impairment of platelet aggregation.

Time frame: Baseline, Day 8, Day 14

Post-Baseline Platelet Reactivity on Days 8 and 14: Aspirin Reaction Units (ARU) Assay

Platelet reactivity, as measured by VerifyNow ARU assay, and presented as number of participants with ≤ 549 ARU or \> 549 ARU post-baseline (Days 8 and 14), by baseline category. Aspirin irreversibly inhibits cyclooxygenase 1, which converts arachidonic acid to thromboxane A2, which in turn is involved in the activation of the glycoprotein (GP)IIb/IIIa receptor necessary to initiate platelet aggregation. Impairment of platelet aggregation of the aspirin type is defined for the VerifyNow aspirin assay as values ≤ 549 ARU.

Time frame: Baseline, Day 8, Day 14

Change From Study Baseline Over Time in Platelet Function Assessments: PRU Assay

The VerifyNow PRU assay measures effects on platelet activation caused by inhibition of the platelet receptor, P2Y12. This receptor is activated by adenosine 5'-diphosphate (ADP) in the cascade leading to platelet aggregation but can be blocked by P2Y12 inhibitor drugs, such as clopidogrel. Blockage of this receptor diminishes platelet activation and the ability of platelets to bind to fibrinogen. VerifyNow PRU assay values \<180 PRU indicate impairment of platelet aggregation.

Time frame: Study Baseline (Day 1 predose), Day 8 (predose AM), Day 14 (predose AM)

Change From Study Baseline Over Time in Platelet Function Assessments: ARU Assay

Aspirin irreversibly inhibits cyclooxygenase 1, which converts arachidonic acid to thromboxane A2, which in turn is involved in the activation of the GPIIb IIIa receptor necessary to initiate platelet aggregation. Impairment of platelet aggregation of the aspirin type is defined for the VerifyNow aspirin assay as values ≤ 549 ARU.

Time frame: Study Baseline (Day 1 predose), Day 8 (pre AM dose), Day 14 (pre AM dose)

Percent Change From Study Baseline Over Time in HOMA-IR in Participants Without Concomitant Use of Insulin

Blood samples were taken for fasting glucose and insulin levels. From these results, insulin resistance was then estimated using the updated homeostasis model assessment method for insulin resistance (HOMA-IR) computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Typically a cutoff of HOMA-IR for identifying those with insulin resistance is 2.5.

Time frame: Study baseline (defined as the last non-missing assessment before the first administration of study drug), Day 8, pre-AM dose, Day 15

IW-1973 Pharmacokinetics: Area Under the Plasma Concentration Time Curve During a Dosing Interval (AUCtau) on Days 1 and 7

Equivalent to AUC from time 0 to the last measurable concentration (AUClast), with time of last measurable concentration (Tlast)=12 hours for BID dosing and Tlast=24 hours for QD dosing.

Time frame: Days 1 and 7 (AM): 1, 3, and 6 hours postdose

IW-1973 Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) on Days 1 and 7

Time frame: Days 1 and 7 (AM): 1, 3, and 6 hours postdose

IW-1973 Pharmacokinetics: Time to Cmax on Days 1 and 7

Time frame: Days 1 and 7 (AM): 1, 3, and 6 hours postdose

IW-1973 Pharmacokinetics: Trough Plasma Concentrations at the End of the Dosing Interval (Ctrough) on Days 1, 2, 6, 7

Time frame: Days 1 and 7: predose; Day 2 (BID AM): predose; Day 6 (BID PM/QD): predose

IW-1973 Pharmacokinetics: Area Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Plasma Concentration (AUClast) on Days 8 and 14

Time frame: Day 8 and 14: 1, 3, 6h (± 5 min) postdose

IW-1973 Pharmacokinetics: AUCtau on Day 14

Time frame: Day 14: 1, 3, 6h (± 5 min) postdose

IW-1973 Pharmacokinetics: Tmax on Days 8 and 14

Time frame: Day 8 and 14: 1, 3, 6h (± 5 min) postdose

IW-1973 Pharmacokinetics: Cmax on Days 8 and 14

Time frame: Day 8 and 14: 1, 3, 6h (± 5 min) postdose

IW-1973 Pharmacokinetics: Ctrough on Days 13 and 14

Time frame: Days 13 and 14: predose

IW-1973 Pharmacokinetics: Apparent Total Body Clearance (CL/F) on Day 14

Time frame: Day 14: 1, 3, 6h (± 5 min) postdose

IW-1973 Pharmacokinetics: Apparent Volume of Distribution During the Terminal Phase (Vz/F) on Day 14

Time frame: Day 14: 1, 3, 6h (± 5 min) postdose

IW-1973 Pharmacokinetics: Apparent Terminal Elimination Phase Half-Life (t1/2)

Time frame: Day 14 (final dose) time points 12 hours, 24 hours, 7 days after final dose (Day 21), and 28 days after final dose(Day 42)

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to TEAEs

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with study treatment. An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death; life-threatening; hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; important medical events. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. AEs of clinical interest (AECI) included those related to bleeding and to hypotension. Study drug causality as assessed by the Investigator who was blinded to study drug assignment.

Time frame: From first dose of study drug to End of Trial Visit (42 [± 3] days)

Number of Participants With Clinically Meaningful Postbaseline Laboratory Test Results

Time frame: From first dose of study drug to End of Trial Visit (42 [± 3] days)

Number of Participants With Notable Changes in Postbaseline Blood Pressure and Heart Rate Values

Supine systolic blood pressure (SSBP): ≥ 180 mmHg and increase (↑) from baseline (BL) ≥ 30 mmHg; ≤ 90 mmHg and decrease (↓) from BL ≥ 30 mmHg. Supine diastolic blood pressure (SDBP): ≥ 105 mmHg and ↑ from BL ≥ 20 mmHg; ≤ 50 mmHg and ↓ from BL ≥ 20 mmHg. Supine heart rate (SHR): ≥ 110 bpm and ↑ from BL ≥ 20 bpm; ≤ 50 bpm and ↓ from BL ≥ 20 bpm. Standing systolic blood pressure (StSBP): ≥ 180 mmHg and increase (↑) from baseline (BL) ≥ 30 mmHg; ≤ 90 mmHg and decrease (↓) from BL ≥ 30 mmHg. Standing Diastolic Blood Pressure (StDBP): ≥ 105 mmHg and ↑ from BL ≥ 20 mmHg; ≤ 50 mmHg and ↓ from BL ≥ 20 mmHg. Standing heart rate (StHR): ≥ 110 bpm and ↑ from BL ≥ 20 bpm; ≤ 50 bpm and ↓ from BL ≥ 20 bpm. Orthostatic systolic blood pressure (SBP): ↓ \> 20 mmHg from supine to standing. Orthostatic diastolic blood pressure (DBP): ↓ \> 15 mmHg from supine to standing. Orthostatic HR: ↓ \> 30 bpm from supine to standing.

Time frame: From first dose of study drug to End of Trial Visit (42 [± 3] days)

Number of Participants With Clinically Significant Post-Randomization Physical Examination Findings

Physical examinations included examination and assessment of the following: general appearance, lymph nodes, skin, cardiovascular system, head, eyes, ears, nose, and throat, central nervous system, respiratory system, neck, peripheral nervous system, abdomen/liver/spleen, musculoskeletal system.

Time frame: Post-randomization to End of Trial Visit (42 [± 3] days)

Number of Participants With Clinically Significant Postbaseline 12-Lead Electrocardiogram (ECG) Results

Time frame: From first dose of study drug to End of Trial Visit (42 [± 3] days)

Change From Study Baseline Over Time in Estimated Glomerular Filtration Rate (eGFR)

Time frame: Study Baseline, Day 15/Discharge, Day 42/End of Trial